A Mounjaro prescription may be available online in the UK through registered pharmacies and private prescribing services, but only after a clinical assessment confirms that it is suitable for you under current MHRA licensing criteria for weight management. If you are an adult aged 18 or over and are considering prescription weight loss treatment, it is important to understand whether Mounjaro is appropriate for your individual circumstances and can be prescribed safely with medical guidance.
Mounjaro has become one of the most talked about weight loss medicines in the UK following the clinical trial results for tirzepatide. Clinical studies found that people taking tirzepatide achieved greater average weight loss than those taking a placebo when it was used alongside a reduced calorie diet and increased physical activity. However, everyone responds differently, and individual results vary depending on factors such as your starting weight, lifestyle changes, and how your body responds to treatment.
It is also important to understand how Mounjaro works, how the online prescribing process works, how the dose increases over time, the possible side effects, costs, storage requirements, and how the medicine fits into a long term weight management plan.
This guide brings together NICE guidance, NHS aligned information and clinical trial data to explain what Mounjaro is, how it works, who may be eligible, how to use it safely and how online private prescribing works. It is designed to provide general information and should not replace advice or treatment decisions made by your prescriber.
Key Facts About Mounjaro at a Glance
| Fact | Detail |
|---|---|
| Active ingredient | Tirzepatide, a dual GIP/GLP-1 receptor agonist |
| Manufacturer | Eli Lilly |
| Administration | Once-weekly subcutaneous (under the skin) injection, via pre-filled pen |
| Available strengths | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg |
| UK licence for type 2 diabetes | Since October 2022 |
| UK licence for weight management | Since November 2023 |
| NICE recommendation for NHS-funded weight management | NICE TA1026, published December 2024 |
| Trial evidence | SURMOUNT-1, 2,539 participants, 72 weeks |
| Also marketed as | Zepbound (US brand name for tirzepatide, weight management indication) |
What Is Mounjaro and How Does It Work?
Mounjaro is the brand name for tirzepatide, a prescription medicine used for type 2 diabetes and weight management in eligible adults. It belongs to a group of medicines that work on two naturally occurring gut hormone pathways: GIP (glucose dependent insulinotropic polypeptide) and GLP 1 (glucagon like peptide 1).
These hormones are released after eating and play a role in appetite regulation, digestion, and insulin release. By acting on both GIP and GLP 1 receptors, tirzepatide helps regulate these processes and is intended to support weight management and blood glucose control when prescribed as part of an overall treatment plan.
In simple terms, Mounjaro works by helping the body release insulin when blood glucose levels rise, slowing digestion so food stays in the stomach for longer, and helping to reduce appetite. It is given once a week using a pre filled injection pen and is intended to be used alongside a reduced calorie diet and increased physical activity, rather than on its own.
Mounjaro is licensed in the UK for adults with type 2 diabetes and for weight management in adults who meet specific eligibility criteria. Before prescribing treatment, your prescriber will assess your health, medical history, and individual circumstances to decide whether it is suitable for you.
Interest in medicines such as Mounjaro has grown as more people look for additional support with weight management. NHS England guidance highlights the increasing number of adults living with overweight and obesity, which has led to greater awareness of prescription weight management treatments, including GIP and GLP 1 medicines.
Is Mounjaro Available in the UK, and Who Can Access It?
Mounjaro is a prescription only medicine in the UK and can only be supplied after an appropriate clinical assessment.
The Medicines and Healthcare products Regulatory Agency (MHRA) first licensed tirzepatide for type 2 diabetes in October 2022 and later extended its licence for weight management in adults aged 18 and over in November 2023.
For weight management, Mounjaro may be suitable for adults with a BMI of 30 kg/m2 or above, or for adults with a BMI between 27 and 30 kg/m2 who also have at least one weight related health condition, such as prediabetes, high blood pressure, high cholesterol, or cardiovascular disease. It is intended to be used alongside a reduced calorie diet and increased physical activity.
Private prescribing services generally assess patients using the MHRA licensed criteria. However, meeting these criteria does not automatically mean treatment will be prescribed. Your prescriber will also consider your overall health, medical history, current medications, and any potential risks before deciding whether Mounjaro is suitable for you.
In December 2024, NICE published technology appraisal TA1026, recommending tirzepatide for NHS funded weight management in adults who meet specific eligibility criteria. NHS access follows a separate pathway with stricter requirements and is being introduced in phases.
For people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African Caribbean backgrounds, BMI thresholds may be lower in some clinical guidelines because weight related health risks can occur at lower BMI levels in these groups.
Whether you are accessing treatment privately or through the NHS, your eligibility is always confirmed through an individual clinical assessment. Your prescriber will decide whether Mounjaro is appropriate based on your personal health and circumstances.
It is important to understand that NHS funded access and private prescribing follow different pathways and eligibility criteria. In both cases, a clinical assessment is required, and suitability is confirmed by a qualified prescriber rather than a BMI calculation alone.
Treatment suitability depends on an individual clinical assessment. Mounjaro should only be used under the supervision of an appropriately qualified prescriber, and results can vary between individuals.
Mounjaro's UK Regulatory Timeline
| Date | Milestone |
|---|---|
| October 2022 | MHRA licenses tirzepatide (Mounjaro) for type 2 diabetes |
| November 2023 | MHRA extends the licence to weight loss and weight management in adults |
| December 2024 | NICE publishes TA1026, recommending tirzepatide for NHS-funded weight management under phased eligibility criteria |
Who Should Speak to Their Doctor Before Starting
If any of the following apply to you, speak with your doctor or prescriber before starting Mounjaro. They can review your medical history and decide whether the treatment is suitable for you:
- Pregnancy, trying to conceive, or breastfeeding
- A personal or family history of certain thyroid cancers
- Certain pancreatic or digestive conditions
- Being under the age of 18
- Taking diabetes medicines, particularly insulin, which may need to be reviewed before starting Mounjaro
- A history of severe gastrointestinal conditions or gallbladder problems
Your prescriber will consider your overall health, medical history, current medicines, and any potential risks before deciding whether Mounjaro is appropriate for you.
Mounjaro Dosage: From First Dose to Maximum Maintenance Dose
Mounjaro treatment does not usually begin at the highest strength. Instead, it typically starts at a lower dose, which may be increased gradually over several weeks if your prescriber feels it is appropriate.
This gradual increase is called dose escalation. It gives your body time to adjust to the medicine and allows your prescriber to monitor how you are responding, including any side effects you may experience.
The dose that is right for you depends on your individual response, treatment goals, and clinical assessment. Not everyone needs to reach the highest available maintenance dose, and your prescriber will recommend the dose that is most suitable for your needs.
Because Mounjaro is a prescription only medicine, your dose should only be changed under the guidance of your prescriber. Do not increase your dose or change your treatment schedule without medical advice.
What If I Miss a Dose?
If you miss a Mounjaro injection, follow the instructions provided with your medication. If you are unsure what to do, speak with your prescriber or pharmacist for advice.
In general, if you remember within the recommended timeframe, you may still be able to take the missed dose. If too much time has passed, it is usually recommended to skip the missed dose and continue with your usual weekly schedule. Do not take two doses to make up for a missed injection.
If you often forget your injections or are finding it difficult to keep to your treatment schedule, speak with your prescriber or pharmacist. They can advise you on the best way to stay on track with your treatment.
Using the Mounjaro Pen
Your Mounjaro pen comes with clear instructions on how to prepare and use it safely. The patient information leaflet included with your medication explains how to prepare the pen, select your dose and inject Mounjaro correctly.
Mounjaro is usually injected once a week under the skin. Common injection sites include the abdomen, thigh or upper arm. Rotating your injection site each week may help reduce irritation from using the same area repeatedly.
If you are using Mounjaro for the first time, your prescriber or pharmacy team can explain how to use the pen and answer any questions you may have. Always follow the instructions provided with your medication, and speak with your healthcare provider if you are unsure about any part of the injection process.
Storage and Travelling With Mounjaro
Mounjaro pens should always be stored according to the manufacturer's instructions and the patient information leaflet supplied with your medication.
Before first use, the pens should generally be kept in a refrigerator. If you are travelling, check the storage guidance provided with your medication and follow the instructions to help keep the pen at the recommended temperature.
If you need to carry Mounjaro while travelling, use appropriate storage where needed and avoid exposing the pen to extreme heat or cold, as this may affect the medicine.
Used pens and needles should be disposed of safely in a suitable sharps bin rather than household waste. If you are unsure how to dispose of them, your pharmacy or healthcare provider can advise you.
If you have any questions about storing, travelling with or disposing of your Mounjaro pen, speak with your pharmacist or prescriber for advice.
What Does the Clinical Trial Evidence Show?
The main clinical evidence for Mounjaro in weight management comes from the SURMOUNT 1 trial, a phase 3 study involving 2,539 adults with obesity, or adults who were overweight with at least one weight related health condition. Participants in the study did not have type 2 diabetes.
After 72 weeks, people taking tirzepatide lost an average of around 15% of their starting body weight on the lowest studied dose and around 20% to 22% on the highest studied dose. Participants taking a placebo lost an average of 2.4%. Everyone in the study also followed a reduced calorie diet and increased physical activity.
It is important to remember that these results are averages from a clinical trial. They do not guarantee how much weight any one person will lose. Your results may vary depending on factors such as your starting weight, prescribed dose, lifestyle changes and how your body responds to treatment.
Possible Side Effects of Mounjaro
Like any prescription medicine, Mounjaro can cause side effects, although not everyone experiences them. The most commonly reported side effects include nausea, diarrhoea, reduced appetite, constipation and stomach discomfort.
These symptoms are often more noticeable when starting treatment or after a dose increase and may improve as your body adjusts to the medicine. However, speak with your healthcare professional if side effects are severe, ongoing or become worse over time.
Some symptoms require more urgent medical advice:
Severe stomach pain that does not go away, which may be a sign of a more serious condition such as pancreatitis or gallbladder problems and should be assessed by a healthcare professional.
Signs of a serious allergic reaction, such as swelling of the face or throat, difficulty breathing or a widespread rash, which require urgent medical attention.
Symptoms of low blood sugar, including shakiness, sweating, confusion or dizziness. This is particularly important if you are also taking insulin or other diabetes medicines.
For people using Mounjaro for type 2 diabetes, rapid improvements in blood sugar levels may sometimes be linked with temporary changes in diabetic retinopathy. If you have existing eye problems related to diabetes, mention this during your consultation.
This is general safety information and does not include every possible side effect. Always read the patient information leaflet provided with your medication and speak with your prescriber or pharmacist if you experience any new or concerning symptoms.
Mounjaro and Other Prescription Medications
Because Mounjaro is a prescription only medicine, your prescriber should always review any other medicines, supplements or treatments you are currently taking before starting treatment.
Two interactions are particularly important to discuss:
If you take insulin or other diabetes medicines that lower blood sugar, using them alongside Mounjaro may increase the risk of low blood sugar. Your prescriber may need to review your current diabetes treatment and adjust it if appropriate.
Mounjaro can slow down how quickly food leaves the stomach, which may affect how some medicines are absorbed. This includes oral contraceptives, so it is important to discuss your contraception plans with your prescriber, who can advise on the most suitable approach.
If you have a history of cardiovascular disease or any other significant health condition, your prescriber will consider this as part of your overall assessment. During treatment, you may also be advised to have health checks or blood tests at intervals recommended by your healthcare professional.
Building a Sustainable Weight Loss Journey Around Mounjaro
Mounjaro is designed to be used alongside a reduced calorie diet and increased physical activity. It is not intended to be used as a standalone weight loss treatment.
Making healthy, sustainable lifestyle changes, such as eating a balanced diet and staying physically active, can help support your weight management journey while using Mounjaro. The best approach will depend on your starting point, health needs and personal circumstances.
It is also normal for weight loss to slow down or reach a plateau during treatment. A weight loss plateau means your weight stays the same for a period of time, even if you are continuing your treatment and healthy lifestyle habits. This does not necessarily mean the medicine has stopped working. If you notice your progress has slowed, speak with your prescriber before making any changes to your treatment. Do not change your dose without medical advice.
Building healthy habits during treatment can also make it easier to maintain your progress over time. After stopping any weight loss medicine, some people may regain weight, so having a long term plan for healthy eating and regular physical activity remains an important part of weight management.
Mounjaro is one of several prescription medicines available for weight management in the UK. Depending on your health, treatment goals and personal preferences, your prescriber may also discuss other suitable options, including medicines such as orlistat or non medical approaches to support weight management.
How Mounjaro Compares to Other Weight Loss Treatments
TABLE: Comparison
| Option | Type | Mechanism | Notes |
|---|---|---|---|
| Mounjaro (tirzepatide) | Weekly injection | Dual GIP/GLP-1 receptor agonist | NICE TA1026; SURMOUNT-1 trial data as above |
| Wegovy (semaglutide) | Weekly injection | GLP-1 receptor agonist | Separately NICE-appraised; different trial evidence base |
| Oral GLP-1 tablets | Daily tablet | GLP-1 receptor agonist | Needle-free; no cold-chain storage required |
| Orlistat | Oral capsule | Reduces fat absorption in the gut | Non-injectable, non-GLP-1 weight loss pill with a different mechanism |
This comparison is for general information only and does not suggest that one treatment is more effective than another. The right option depends on individual clinical circumstances and should be discussed with a healthcare professional.
Mounjaro Cost in the UK
Mounjaro is not currently available through general NHS prescribing for weight management outside the phased, criteria based NHS rollout described earlier. For many people choosing private treatment, the cost is paid directly to the provider.
The cost of Mounjaro can vary depending on the pen strength, the provider, consultation fees and delivery charges. As treatment usually starts at a lower dose and may increase gradually, lower strengths are often priced differently from higher maintenance strengths.
Some providers also offer multi pen bundles, which may reduce the overall cost per pen compared with buying individual pens. When comparing prices, it is worth checking what is included, such as the clinical consultation, prescription, medication and delivery, rather than looking only at the advertised medicine price.
Prices may change over time and vary between providers, so always check the latest pricing information before starting treatment.
Mounjaro Glossary: Terms You Will Come Across
Tirzepatide: The active ingredient in Mounjaro.
GIP (glucose dependent insulinotropic polypeptide) and GLP 1 (glucagon like peptide 1): Two naturally occurring gut hormone pathways that tirzepatide works on, which may help regulate appetite and blood glucose levels.
Dose escalation: The gradual increase in your dose from the starting strength to a maintenance dose, if your prescriber considers it appropriate.
Maximum maintenance dose: The highest dose your prescriber may recommend based on your individual response and clinical assessment. Not everyone needs to reach this dose.
Subcutaneous injection: An injection given just under the skin. This is how Mounjaro is administered.
BMI (body mass index): A measurement based on your height and weight that is used alongside other health factors when assessing whether treatment may be suitable for you.
Zepbound: The brand name used by Eli Lilly in the United States for tirzepatide when it is prescribed specifically for weight management.
Getting Started: What to Expect From a Weight Loss Service
If you are looking to access Mounjaro online, a reliable weight loss service should begin with a genuine clinical assessment rather than an automatic approval process.
You may be asked about your medical history, current medicines, weight related health conditions and previous weight loss efforts. This information helps a prescriber decide whether Mounjaro is suitable for you and whether another option may be more appropriate.
If you are not eligible for treatment, a responsible healthcare provider should explain the reason and guide you towards suitable alternatives rather than approving medication without proper checks.
If treatment is approved, you should receive clear information about your starting dose, how dose increases work, how to store your Mounjaro pens safely and who to contact if you have questions during treatment.
Ongoing support from a healthcare professional or pharmacy team is an important part of a safe weight management journey, both when starting treatment and as your plan develops over time.
